£44m Project to Develop Nasal Spray Vaccines through Human Challenge Trials
Imperial College London's MusiCC project aims to revolutionize vaccine development by targeting mucosal immunity to block virus transmission and reduce disease severity.
A £44 million project led by Imperial College London aims to develop nasal spray vaccines through human challenge trials. These trials involve deliberately infecting healthy volunteers with diseases like Covid-19 to test the efficacy of next-generation vaccines.
The goal is to create vaccines that not only reduce disease severity but also prevent virus transmission, potentially aiding in ending pandemics swiftly. By targeting mucosal immunity in the nose and lungs, these nasal spray vaccines aim to block virus spread at the point of entry and exit in the body.
The project, named MusiCC, focuses on betacoronaviruses, including Sars-Cov-2, Mers, and common cold viruses. It is not clear what types of vaccine technology will be used in the trials (such as mRNA).
Key Details of the Project:
Objective: The project aims to develop vaccines that can stop the transmission of viruses, which is crucial for swiftly ending pandemics and epidemics [1].
Funding: The project is co-funded by the Coalition for Epidemic Preparedness Innovations (Cepi) and Imperial College London.
Duration: The project is set to run for five years.
Research Focus: The project, called MusiCC, will test the potential of several nasal spray vaccines against betacoronaviruses, including Sars-Cov-2, Mers, and seasonal common cold viruses.
Human Challenge Trials: The project will be based on human challenge trials, where healthy volunteers will be deliberately infected with diseases, including Covid-19, to test the effectiveness of the nasal spray vaccines.
Mucosal Immunity: The project aims to trigger mucosal immunity, which is believed to block infections, by delivering the vaccine directly into the nose and lungs instead of through muscle tissue injections.
Global Collaboration: The project will involve multiple sites worldwide, allowing for concurrent trials and a broader understanding of the vaccines' effectiveness.
Note: Safe over the counter nasal sprays can already be used to help reduce viral load in the nasal passages, including saline, xylitol, and colloidal silver hydrosols.
For natural approaches to building immunity, talk to one of our practitioners in the Wholistic Clinic.
In UK they have been jabbing children at school (schools are jab centers in UK, jabbed at the comfort of your school halls) since 2013. Kids have been trained to put thing up their nose from the age of 3.5-4 (primary school age) with Flumist nasal flu vaccination program delivered at school and the daily testing (than changed frequency) at school program during the pandemic.
David Cameron was Prime minister in UK when flumist jabbing at school started. This is they year of Great Britain taking the lead at G8.
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/551676/Childhood_flu_programme_information_for_healthcare_practitioners.pdf
schoolnhttps://assets.publishing.service.gov.uk/media/64957c5ede8682000cbc8d22/UKHSA-12652-flu-vaccination-programme-briefing-for-headteachers-2023-2024.pdf
https://www.medicines.org.uk/emc/product/3296/smpc
Marketing authorization:
AstraZeneca UK Limited,
1 Francis Crick Avenue,
Cambridge,
CB2 0AA,
UK
Date of first authorisation: 04 December 2013
Date of latest renewal: 20 November 2018
Like all the PCR testing that many never questioned , i would think anything shoved in the nasal passage by Big Pharma mafia will be easily accepted . Kind of wonder if they are building plants that have solutions to nasal and sinus ca , as one example of what could go wrong with this stuff that will be rapidly approved. I've been called a cynic and I'm surprised there aren't more of us .